Immunotherapy of kidney cancer. Where do the T lymphocytes go in kidney cancer?

我们研究的目的：-（CD 4 + AP/CD 8 + DAB）、CD 103 DAB、CD 39 DAB的表达将是 在一组肾细胞癌中通过IHC确定-图像采集将使用 Zeiss扫描仪和上皮、肿瘤和间质区域将使用 QuPath 0.2.0-m8软件。坏死区域、血细胞、血管被排除， 肿瘤区域。- 通过颜色去卷积检测内的阳性免疫细胞， 门槛调整。- 通过光密度总和测量阳性细胞检测， 创建的测量图。- 检测数量，阳性和阴性， 将记录阳性细胞和每mm_2的阳性细胞数用于我们的分析。- 将在一些样品中评估聚类图，以确定是否存在特定的 免疫阳性细胞与肿瘤细胞的关系。- CD 103和CD 39细胞 将分析肿瘤和良性上皮之间的位置以及临床和病理 数据将与我们的结果相关联。

Aims of our study: - Expression of (CD4+ AP/ CD8+ DAB), CD103 DAB, CD39 DAB will be determine by IHC in a group of renal cell carcinomas - Images acquisition will be done using a Zeiss scanner and epithelial, tumor and stroma areas will be annotated on each sample using the QuPath 0.2.0-m8 software. Areas of necrosis, blood cells, blood vessels were excluded from the tumor areas. - Positive immune cells within will be detected by color deconvolution and threshold adjustments. - Positive cell detection was measure by optical density sum, and measurements maps created. - Number of detections, positive ad negative, percentage of positive cells and number pf positive cells per mm_2 will be recorded for our analysis. - Cluster maps will be evaluated in some samples to determine the presence or not of a specific pattern of positive immune cell in relation with tumor ones. - The CD103 and CD39 cells location will be analyzed between tumor and benign epithelium and clinical and pathological data will be correlated with our results.